Antigen Presenting Cells
Density
Current Density
Target Cell Response to Hormones
Bulk Density of Aggregate
Strain-Energy Density
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 24, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Sneha Ramakrishna1, Steven L Highfill2, Zachary Walsh1,3,4
1Pediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland.
Low CD22 expression limits chimeric antigen receptor T-cell (CART) therapy for acute lymphoblastic leukemia (ALL). Upregulating CD22 with Bryostatin1 enhances CART efficacy and prolongs remission duration in patients with leukemia and lymphoma.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: